Cm In Short Axis Research Articles

Hodgkin lymphoma in the bone marrow aspirate of a young patient with human immunodeficiency virus.

Hodgkin lymphoma in the bone marrow aspirate of a young patient with human immunodeficiency virus.

Development and Validation of Diagnostic Interpretation Criteria for Evaluation of F-18 Fluoromisonidazole Hypoxia PET/CT – Inter-Reader Reliability and Accuracy

<h3>Purpose/Objective(s)</h3> F-18 Fluoromisonidazole (FMISO) is a robust imaging biomarker for tumor hypoxia. Hypoxia limits effective cancer treatment, specifically radiotherapy in head and neck cancers. We have completed and have ongoing trials using hypoxia imaging to guide radiation dose de-escalation. To ensure wide applicability, we sought to develop and validate standardized qualitative and quantitative criteria to accurately and reliably interpret clinical FMISO PET/CT images. <h3>Materials/Methods</h3> All HPV+ oropharyngeal cancer patients who had FMISO PET/CT imaging before and about 2 weeks into chemoradiation therapy and pre-treatment F-18 FDG PET/CT were included. 4 independent nuclear medicine (NM) physicians with varying clinical experience of 1, 3, 5, and 15 years with no FMISO experience interpreted images. Training and reference interpretations were performed by a 5^th NM physician with 30 years of clinical and 15 years of FMISO experience. Suspicious cervical lymph nodes (LN) > 1 cm in short axis with abnormal FDG avidity on FDG PET/CT were categorized as positive or negative for FMISO uptake. A LN was considered positive if it demonstrated SUVmax visually greater than floor of mouth (FOM). FMISO SUVmax of the LN and FOM were obtained using a 3D VOI. The training and validation process consisted of: (1) initial instruction; (2) practice interpretation; (3) one on one re-training on contentious group reads; (4) final group training; (5) validation interpretation of new scans. Qualitative, visual comparison of FMISO uptake in LN to FOM, and quantitative, ratio of FMISO SUVmax of LN to FOM, were analyzed. The Fleiss κ coefficient (κ) was calculated to measure inter-reader agreement. <h3>Results</h3> 192 FMISO scans were included. Qualitative criteria mean sensitivity and specificity (SE/SP) after initial instruction were 0.773 and 0.809. κ was 0.338. Mean SE/SP after additional training were 0.976 and 0.869. κ was 0.864 [95%CI: 0.782 to 0.944]. For the quantitative criteria, ROC curve analysis was used to estimate the best threshold by maximizing the Youden index, which was determined to be SUVmax LN/SUVmax FOM > 1.2. Quantitative criteria mean SE/SP after additional training were 0.896 and 0.953. κ was 0.859 (95%CI: 0.761 to 0.944). The quantitative criteria alone demonstrated a lower sensitivity than the qualitative, 0.896 vs. 0.976. Therefore, we suggest using a hybrid method with quantitative criteria as a guide with the ultimate decision based on qualitative assessment to minimize the number of patients with false negatives and subsequent undertreatment. <h3>Conclusion</h3> The hybrid qualitative/quantitative diagnostic interpretation criteria developed for evaluating FMISO PET/CT in combination with dedicated training has substantial inter-reader agreement and excellent diagnostic performance. This suggests that multi-institutional studies that employ FMISO PET for patient stratification in prospective trials are feasible and can be implemented.

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

TPS4617 Background: Patients [pts] withlymph node positive (LN+), non-metastatic bladder cancer (BC) have a better prognosis than those with metastatic (M1) disease. However, this population is under-represented in advanced bladder trials and ineligible for bladder-sparing trials. Therefore, there have been no larger prospective trials establishing the standard of care in LN+ BC. Given the promise of immunotherapy in advanced BC and potential synergy between immunotherapy and radiation, INSPIRE was designed to determine the role of concurrent and adjuvant durvalumab (durva) in this patient population when treated with induction chemotherapy (IC) followed by concurrent chemoRT. Methods: This is a randomized phase II study that is enrolling BC pts with stage III [N1-3 M0], pure or mixed urothelial cancer. Pts must have received ≥3 cycles of IC [either before or after registration, prior to randomization] without progression. LN+ is defined as radiologically LN ≥1.0 cm in short axis, with or without biopsy prior to IC. As long as pts do not progress on induction chemotherapy, they will be randomized to chemoRT+/- durva using 5 stratification factors (Simon Pocock minimization method) a) IC prior vs. post registration b) cisplatin vs non-cisplatin regimen during RT c) LN size d) response to IC e) extent of TURBT. Pts on the chemoRT+durva arm will get chemotherapy per physician choice + IMRT + 3 x doses of Q3wk durva for 6.5-8 wks, whereas those on the control arm will get chemoRT alone. The primary end point is clinical complete response [CR], defined as no radiologically measurable disease in the LNs and negative cystoscopy and bladder biopsy 8-10 weeks post-chemoRT +/- durva. Pts on the chemoRT + durva arm who have a CR or clinical benefit ( &gt; T0 and ≤T2 in bladder per cystoscopy, biopsy + CR/PR/SD in LN by imaging) will get adjuvant Q4wk durva for 9 doses, while those on the chemoRT arm will undergo observation. Secondary end points include OS, PFS, bladder-intact event-free survival, rate of toxicity and salvage cystectomy. This study is designed to detect an improvement of 25% in clinical CR between both arms (37.5% to 62.5%). A total accrual of 114 pts (in order to enroll 92 evaluable pts) will provide 81% power to detect this difference using a Fisher’s exact test (assuming 10% drop out + anticipating that 20% chemotherapy-naïve pts will progress post IC). We are banking blood and primary tumor tissue pre- and post-chemoRT in both groups. The study was activated in August 2020 and accrual is ongoing. We expanded eligibility to include N3 in 9/2021. INSPIRE is the first prospective study designed for only LN+ BC and will define both short-term and long-term outcomes for bladder sparing in this patient population and has the potential to define a new treatment strategy for stage III BC. Clinical trial information: NCT04216290.

Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer

Objective(s)To assess incidence and oncologic outcomes in women with advanced epithelial ovarian cancer (EOC) with inguinal lymph node metastasis (ILNM) at diagnosis. MethodsAn IRB-approved, retrospective single-institution cohort study was performed in women with stage III/IV EOC from 2009 to 2017. Patients with inguinal lymphadenopathy (defined as >1 cm in short axis) clinically or radiographically were identified. The impact of ILNM on progression-free survival (PFS) and overall survival (OS) were assessed. ResultsOf the 562 women with advanced EOC, 18 (3.2%) had ILNM at diagnosis, accounting for 25.7% of all patients with stage IVB disease (n = 70). Five patients (27.7%) had a known genetic predisposition for EOC, including BRCA1 (11.1%, n = 2), BRCA2 (11.1%, n = 2) and BRIP1 (5.6%, n = 1). The majority of patients underwent optimal primary cytoreductive surgery (CRS), including debulking of inguinal nodal metastasis (83.3%, n = 15), with 50% (n = 9) having no gross residual disease after surgery. There was no difference in PFS (19.9 vs. 19.9 vs. 17.2 months, p = 0.84) or OS (137.2 vs. 52.9 vs. 67.6 months, p = 0.29) in women with stage III/IV with ILNM, stage III/IV without ILNM, and stage IVB disease without ILNM, respectively. Progression-free survival was improved in women with ILNM who underwent an optimal resection to no macroscopic disease vs. non-optimal resection (27.4 vs. 14.3 months, p = 0.019). Median overall survival at the time of analysis did not reach statistical significance (137.2 vs. 57.3 months, p = 0.24). Conclusion(s)In this retrospective cohort study, 3.2% of women with advanced EOC presented with ILNM at diagnosis. Although ILNM did not portend worse clinical outcomes compared to all Stage III/IV and Stage IVB patients, respectively, resection to no gross residual disease was associated with improved PFS.

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

TPS594 Background: Patients [pts] withlymph node positive (LN+), non-metastatic bladder cancer (BC) have a better prognosis than those with metastatic (M1) disease. However, this population is under-represented in advanced bladder trials and ineligible for bladder-sparing trials. Therefore, there have been no larger prospective trials establishing the standard of care in LN+ BC. Given the promise of immunotherapy in advanced BC and potential synergy between immunotherapy and radiation, INSPIRE was designed to determine the role of concurrent and adjuvant durvalumab (durva) in this patient population when treated with induction chemotherapy (IC) followed by concurrent chemoRT. Methods: This is a randomized phase II study that is enrolling BC pts with stage III [N1-3 M0], pure or mixed urothelial cancer. Pts must have received ≥3 cycles of IC [either before or after registration, prior to randomization] without progression. LN+ is defined as radiologically LN ≥1.0 cm in short axis, with or without biopsy prior to IC. As long as pts do not progress on induction chemotherapy, they will be randomized to chemoRT+/- durva using 5 stratification factors (Simon Pocock minimization method) a) IC prior vs. post registration b) cisplatin vs non-cisplatin regimen during RT c) LN size d) response to IC e) extent of TURBT. Pts on the chemoRT+durva arm will get chemotherapy per physician choice + IMRT + 3 x doses of Q3wk durva for 6.5-8 wks, whereas those on the control arm will get chemoRT alone. The primary end point is clinical complete response [CR], defined as no radiologically measurable disease in the LNs and negative cystoscopy and bladder biopsy 8-10 weeks post-chemoRT +/- durva. Pts on the chemoRT + durva arm who have a CR or clinical benefit (&gt;T0 and ≤T2 in bladder per cystoscopy, biopsy + CR/PR/SD in LN by imaging) will get adjuvant Q4wk durva for 9 doses, while those on the chemoRT arm will undergo observation. Secondary end points include OS, PFS, bladder-intact event-free survival, rate of toxicity and salvage cystectomy. This study is designed to detect an absolute improvement of 25% in clinical CR between both arms (37.5% to 62.5%). The accrual goal is 114, assuming 10% drop out + anticipating that 20% chemotherapy-naïve pts will progress post IC, and 92 evaluable pts that will provide 81% power to detect this difference using a Fisher’s exact test. We are banking blood and primary tumor tissue pre- and post-chemoRT in both groups. The study was activated in August 2020 and accrual is ongoing. We expanded eligibility to include N3 in 9/2021. INSPIRE is the first prospective study designed for only LN+ BC and will define both short-term and long-term outcomes for bladder sparing in this patient population and has the potential to define a new treatment strategy for stage III BC. Clinical trial information: NCT04216290.

Percutaneous Polidocanol Injection as an Alternative Treatment in Differentiated Thyroid Cancer Oligometastasis

We report a case of a 49‑year‑old female with papillary thyroid cancer, hospitalized for progressive dysphonia of 2 months of evolution with a neck USG reporting right lymph node level III of 0.97 cm in short axis, suspected of malignancy. We administered 2 doses of percutaneous polidocanol injection. In the follow- up there was complete disappearance of the node

N3 hilar sampling decision in the staging of mediastinal lung cancer.

There is insufficient evidence for the sampling of morphometabolically normal N3 hilar lymph nodes https://bit.ly/3gWcar7

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

TPS4590 Background: Patients [pts] withlymph node positive (LN+), non-metastatic bladder cancer (BC) have a better prognosis than those with metastatic (M1) disease. However, this population is under-represented in advanced bladder trials and ineligible for bladder-sparing trials. Therefore, there have been no larger prospective trials establishing the standard of care in LN+ BC. Given the promise of immunotherapy in advanced BC and potential synergy between immunotherapy and radiation, INSPIRE was designed to determine the role of concurrent and adjuvant durvalumab (durva) in this patient population when treated with induction chemotherapy (IC) followed by concurrent chemoRT. Methods: This is a randomized phase II study that is enrolling BC pts with stage III [N1-2 M0], pure or mixed urothelial cancer. Pts must have received ≥3 cycles of IC [either before or after registration, prior to randomization] without progression. LN+ is defined as radiologically LN ≥1.0 cm in short axis, with or without biopsy prior to IC. As long as pts do not progress on induction chemotherapy, they will be randomized to chemoRT+/- durva using 5 stratification factors (Simon Pocock minimization method) a) IC prior vs. post registration b) cisplatin vs non-cisplatin regimen during RT c) LN size d) response to IC e) extent of TURBT. Pts on the chemoRT+durva arm will get chemotherapy per physician choice + IMRT + 3 x doses of Q3wk durva for 6.5-8 wks, whereas those on the control arm will get chemoRT alone. The primary end point is clinical complete response [CR], defined as no radiologically measurable disease in the LNs and negative cystoscopy and bladder biopsy 8-10 weeks post-chemoRT +/- durva. Pts on the chemoRT + durva arm who have a CR or clinical benefit ( &gt; T0 and ≤T2 in bladder per cystoscopy, biopsy + CR/PR/SD in LN by imaging) will get adjuvant Q4wk durva for 9 doses, while those on the chemoRT arm will undergo observation. Secondary end points include OS, PFS, bladder-intact event-free survival, rate of toxicity and salvage cystectomy. This study is designed to detect an improvement of 25% in clinical CR between both arms (37.5% to 62.5%). A total accrual of 114 pts (in order to enroll 92 evaluable pts) will provide 81% power to detect this difference using a Fisher’s exact test (assuming 10% drop out + anticipating that 20% chemotherapy-naïve pts will progress post IC). We are banking blood and primary tumor tissue pre- and post-chemoRT in both groups. The study was activated in August 2020 and accrual is ongoing. INSPIRE is the first prospective study designed for only LN+ BC and will define both short-term and long-term outcomes for bladder sparing in this patient population and has the potential to define a new treatment strategy for stage III BC. Clinical trial information: NCT04216290.

Validation of National Comprehensive Cancer Network Guidelines (NCCN) at a single institution.

e20556 Background: Invasive mediastinal staging is necessary to identify locally advanced non-small cell lung cancer (NSCLC). We sought to validate NCCN guidelines for invasive mediastinal staging. Methods: We retrospectively reviewed all patients who had curative lung resection for pathologically confirmed NSCLC from October 2018 to December 2019. We excluded patients who had induction therapy without undergoing invasive mediastinal staging first. We evaluated methods of mediastinal staging, staging results, and final pathology. Indications for staging were one or more of the following; mediastinal lymph nodes &gt; 1.0cm in short axis, Standardized Uptake Value of &gt; 3.0 on Positron Emission Tomography, &gt; 50% of tumor on medial side of mid-clavicular line (central vs peripheral), or peripheral lesion &gt; 3.0cm in diameter. Staging methods were mediastinoscopy, endobronchial ultrasound (EBUS), and video-assisted thoracoscopic surgery (VATS) ipsilateral mediastinal staging before resection of main tumor. Results: In total, 457 lung resections were performed. Staging was done in 144/275 indicated cases (52.4%). Mediastinoscopy was completed in 49 patients, with 20.4% (n = 10) N2-positive. The false negative rate of mediastinoscopy was 4.1% (n = 2 at station 7). EBUS was performed in 64 patients and 21.9% (n = 14) were N2 positive. The false negative rate for EBUS was 3.1% (n = 2 at station 7). Two mediastinoscopy and 9 EBUS patients had 0 N2 stations sampled. None of the patients were ultimately N2 positive. Staging of three mediastinal stations (4L, 4R, and 7) was done in 26/49 mediastinoscopies and 15/64 EBUS. Of 20 patients who had VATS ipsilateral mediastinal staging, none were N2 positive and there were 0 false negatives. This left 131 patients who did not received indicated staging. The most common indication in this group was central location, 83.2% (n = 109). Four of these unstaged patients were N2 positive at resection (3.1%). The sole indication for these 4 patients was a centrally located tumor. Clinical tumor sizes were 1.2 cm, 1.3 cm, 1.5 cm, and 1.9 cm. Overall, the N2-positive rate of the staged group was 24/144 (16.7%) vs 4/131 (3.1%) N2 positive in the unstaged group, p &lt; 0.001. Conclusions: The current NCCN staging guidelines accurately reflect the risk of N2 disease for NSCLC. The indication of central location for tumors may benefit from being reevaluated in a larger cohort, particularly given efficacy of adjuvant therapy.

Percutaneous Polidocanol Injection as an Alternative Treatment in Differentiated Thyroid Cancer Oligometastasis

Introduction: Differentiated thyroid cancer (DTC) presents central lymph node metastasis in 20-50% and lateral in 12-86% of patients, the treatment of choice is surgical reintervention but it carries a higher risk of complications secondary to fibrosis formation in the surgical bed. Alternative nonsurgical therapies such as percutaneous ethanol injection (PEI), radiofrequency or laser ablation have been described. Objective: To report a case of oligometastasis in CDT which underwent percutaneous polidocanol injection (PPI). Clinical Case: A 35-year-old female who underwent a total thyroidectomy in 06-2019 for papillary thyroid cancer (AJCC: stage I/ ATA: intermediate risk), and ablative dose of 150 mCi I131, under treatment with levothyroxine 150 mcg/d. Hospitalized 02-2020 for progressive dysphonia of 2 months of evolution, with studies of TSH 0.04 mIU/ml, TgAb 13 IU/ml, Tg 0.5 ng/ml and neck USG: right lymph node level III of 0.97 cm in short axis, suspected of malignancy. Tg washout 4743.72 ng/ml (positive), 1cc of 1% polidocanol is administered, guided by USG. 7 days later with 0.90 cm in short axis, a second dose of 1% polidocanol was administered and a new Tg washout was taken, 2.4 ng/ml (indeterminate). She was reevaluated in the first and fourth months of the procedure, with 0.10 cm in the short axis and complete disappearance of the lesion, respectively. Control studies at the fourth month of TgAb 13 IU/ml, Tg 0.4 ng/ml. Discussion: PEI is described for thyroid cysts and adenomas and for cervical lymph node metastases, this is a minimally invasive procedure in the treatment of lesions smaller than 10 mm but requires multiple sessions and it can cause pain due to extravasation, skin necrosis and damage to the recurrent laryngeal nerve. It requires a follow-up time of up to 65 months, producing a reduction in serum Tg less than 2.4 ng/ml, a decrease in the size of the lesion and disappearance in 46% of the cases. In our center we have experience with PPI in thyroid cysts and adenomas since 2017, this requires fewer sessions and a lower dose, obtaining results of volume reduction in thyroid cysts of 80%. In this case we observed a reduction of 90% in the first month and disappearance in the fourth month, with a significant decrease in Tg washout from the first administration. Conclusion: Polidocanol is safe and effective so it should be considered in the treatment of oligometastasis in DTC.

EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.

TPS500 Background: Patients [pts] withlymph node positive (LN+), non-metastatic bladder cancer (BC) have a better prognosis than those with metastatic (M1) disease. However, this population is under-represented in advanced bladder trials and ineligible for bladder-sparing trials. Therefore, there have been no larger prospective trials establishing the standard of care in LN+ BC. Given the promise of immunotherapy in advanced BC and potential synergy between immunotherapy and radiation, INSPIRE was designed to determine the role of concurrent and adjuvant durvalumab (durva) in this patient population when treated with induction chemotherapy (IC) followed by concurrent chemoRT. Methods: This is a randomized phase II study that is enrolling BC pts with stage III (N1-2 M0), pure or mixed urothelial cancer. Pts must have received ≥3 cycles of IC [either before or after registration, prior to randomization] without progression. LN+ is defined as radiologically LN ≥1.0 cm in short axis, with or without biopsy prior to IC. As long as pts do not progress on induction chemotherapy, they will be randomized to chemoRT+/- durva using 5 stratification factors (Simon Pocock minimization method) a) IC prior vs. post registration b) cisplatin vs non-cisplatin regimen during RT c) LN size d) response to IC e) extent of TURBT. Pts on the chemoRT+durva arm will get chemotherapy per physician choice + IMRT + 3 x doses of Q3wk durva for 6.5-8 wks, whereas those on the control arm will get chemoRT alone. The primary end point is clinical complete response [CR], defined as no radiologically measurable disease in the LNs and negative cystoscopy and bladder biopsy 8-10 weeks post-chemoRT +/- durva. Pts on the chemoRT + durva arm who have a CR or clinical benefit (&gt;T0 and ≤T2 in bladder per cystoscopy, biopsy + CR/PR/SD in LN by imaging) will get adjuvant Q4wk durva for 9 doses, while those on the chemoRT arm will undergo observation. Secondary end points include OS, PFS, bladder-intact event-free survival, rate of toxicity and salvage cystectomy. This study is designed to detect an improvement of 25% in clinical CR between both arms (37.5% to 62.5%). A total accrual of 114 pts (in order to enroll 92 evaluable pts) will provide 81% power to detect this difference using a Fisher’s exact test (assuming 10% drop out + anticipating that 20% chemotherapy-naïve pts will progress post IC). We are banking blood and primary tumor tissue pre- and post-chemoRT in both groups. The study was activated in August 2020 and accrual is ongoing. INSPIRE is the first prospective study designed for only LN+ BC and will define both short-term and long-term outcomes for bladder sparing in this patient population and has the potential to define a new treatment strategy for stage III BC. Clinical trial information: NCT04216290.

CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT.

Evaluate utility of dual energy CT iodine material density images to identify preoperatively nodal positivity in pancreatic cancer patients who underwent neoadjuvant therapy. This IRB approved retrospective study evaluated 62 patients between 2012 and 2016 with proven pancreatic ductal adenocarcinoma, who underwent neoadjuvant therapy, tumor resection and both baseline and preoperative assessment with pancreatic multiphasic rapid switching dual energy CT. Three radiologists in consensus identified on imaging nodes > 0.5cm in short axis, evaluated nodal morphology, size and on each phase density in HU, and concentrations on iodine material density images normalized to the aorta. Of 62 patients, 33 were N0, 20 N1, and 9 N2. Total of 145 lymph nodes were evaluated, with average number of nodes per anatomic site ranging from 1.3 (body tumors) to 5 (uncinate) versus average of 24 and 30 nodes recovered respectively at surgery. Most (N = 44) were pancreatic head tumors. For all patients, regardless of site of primary tumor, the minimum measured iodine value of all of a patient's measured nodes taken as a group on preoperative studies, as normalized to the aorta, was significant at P = 0.041 value in differentiating N0 from N1/2 and ROC analysis showed an AUC of 0.67. With a cutoff of 0.2857, sensitivity was 0.78 and specificity was 0.58, with values < 0.2857 indicative of N1/2. Node morphology and changes in nodal size weren't statistically significant. The dual energy based minimum normalized iodine value of all nodes in the surgical field on preoperative studies has modest utility in differentiating N0 from N1/2, and generally outperformed conventional features for identifying nodal metastases.

Thrombus in giant right atrial appendage aneurysm.

A 57-year-old female with no abnormal disease history presented to our clinic for persistence shortness of breath over 1 year. On admission, the physical examination revealed a heart rate 89 beats/min with sinus rhythm, hepatojugular reflux syndrome, hepatomegaly, and peripheral oedema. No cardiac murmur can be noticed. Chest X-ray revealed a pronounced bulge of the right heart margin (Panel A, arrow), with normal pulmonary vascular markings. Transoesophageal echocardiography detected a giant echolucent mass with intra-cavity thrombus (Panel B, arrowhead, 6.02 cm × 3.70 cm; Supplementary material online, Video S1). Computerized tomography angiography (CTA) confirmed a giant aneurysm with intra-cavity thrombus arising from the right atrial appendage, compressing the right ventricle (Panels C and D, 8.30 cm × 6.53 cm in short-axis, arrowhead, and asterisk). The patient received surgical intervention under cardiopulmonary bypass. After median sternotomy, the intra-cavity thrombus, which was then removed, could...

Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer

ObjectivesTo assess outcomes and patterns of recurrence in patients with high-grade serous ovarian/tubal/primary peritoneal cancers with radiographic supraclavicular lymphadenopathy at diagnosis.MethodsWe evaluated all patients with newly diagnosed high-grade serous ovarian...

Investigation of patterns of nodal metastases in BRAF mutant lung cancer

Axillary lymph nodes (axLN) are a rare site of nodal metastases in patients with lung cancer. BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2–5% of non-small cell lung carcinomas (NSCLC). A recent study identified a highly unusual pattern of metastatic spread to axLN in patients with BRAF mutated colorectal cancer (CRC). The purpose of the study is to assess the incidence of axLN metastases in BRAF mutated NSCLC.Baseline computed tomography (CT) imaging at diagnosis and all follow up CTs of patients with BRAF mutated NSCLC treated at our institution were retrospectively reviewed by two radiologists for evidence of axLN metastases. Positron emission tomography (PET)/CT was reviewed when available. A control group of patients with non-BRAF mutated NSCLC was assessed. Three criteria were used for the diagnosis of a metastatic node; pathologic confirmation, radiologic size greater ≥1.5cm in short axis diameter or fluorodeoxyglucose avidity on PET/CT and radiologic size ≥1.0cm in short axis diameter.Forty-six patients with BRAF mutated NSCLC and CT images on the institutional PACS were identified. 7 (15%) patients with BRAF mutated NSCLC had axLN metastases using the proposed diagnostic criteria. One patient had a pathologic proven axLN metastasis, 3 had axLNs measuring ≥1.5cm in short axis, and 3 had nodes which were FDG avid on PET/CT and measured ≥1.0cm in short axis. By comparison, 1 of 46 (2%) control patients with non-BRAF mutated NSCLC had axLN metastases. Previous series have reported the prevalence of axLN metastases in patients with NSCLC as 0.61–0.75%.We have found a higher incidence of axLN metastases in BRAF mutated NSCLC patients than described in non-BRAF mutated NSCLC patients. Examination of the axilla should be a routine part of physical examination in this genetically distinct subgroup of lung cancer patients.

Diagnostic performance of convex probe EBUS-TBNA in patients with mediastinal and coexistent endobronchial or peripheral lesions.

To compare the performance of convex probe endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) with conventional endobronchial biopsy (EBB) or transbronchial lung biopsy (TBLB) in patients with mediastinal, and coexisting endobronchial or peripheral lesions.Retrospective review of records of patients undergoing diagnostic EBUS-TBNA and conventional bronchoscopy in 2014.A total of 74 patients had mediastinal, and coexisting endobronchial or peripheral lesions. The detection rate of EBUS-TBNA for mediastinal lesion >1 cm in short axis, EBB for visible exophytic type of endobronchial lesion, and TBLB for peripheral lesion with bronchus sign were 71%, 75%, and 86%, respectively. In contrast, the detection rate of EBUS-TBNA for mediastinal lesion ≤1 cm in short axis, EBB for mucosal hyperemia type of endobronchial lesion, and TBLB for peripheral lesion without bronchus sign were 25%, 63%, and 38%, and improved to 63%, 88%, and 62% respectively by adding EBB or TBLB to EBUS-TBNA, and EBUS-TBNA to EBB or TBLB. Postprocedure bleeding was significantly more common in patients undergoing EBB and TBLB 8 (40%) versus convex probe EBUS-TBNA 2 patients (2.7%, P = 0.0004).EBUS-TBNA is a safer single diagnostic technique compared with EBB or TBLB in patients with mediastinal lesion of >1 cm in size, and coexisting exophytic type of endobronchial lesion, or peripheral lesion with bronchus sign. However, it requires combining with EBB or TBLB and vice versa to optimize yield when mediastinal lesion is ≤1 cm in size, and coexisting endobronchial and peripheral lesions lack exophytic nature, and bronchus sign, respectively.

Targeted transperineal biopsy of the prostate has limited additional benefit over background cores for larger MRI-identified tumors

PurposeTo compare histological outcomes in patients undergoing MRI–transrectal ultrasound fusion transperineal (MTTP) prostate biopsy and determine the incremental benefit of targeted cores.MethodsSeventy-six consecutive patients with 89 MRI-identified targets underwent MTTP biopsy. Separate targeted biopsies and background cores were obtained according to a standardized protocol. Target biopsies were considered of added diagnostic value if these cores showed a higher Gleason grade than non-targeted cores taken from the same sector (Group 1, n = 41). Conversely, where background cores demonstrated an equal or higher Gleason grade, target cores were considered to be non-beneficial (Group 2, n = 48).ResultsThere was no significant difference in age, PSA, prostate volume, time-to-biopsy, and number of cores obtained between the groups. A greater proportion of target cores were positive for cancer (158/228; 69.3 %) compared to background (344/1881; 18.38 %). The median target volume was 0.54 cm3 for Group 1 (range 0.09–2.79 cm3) and 1.65 cm3 for Group 2 (0.3–9.07 cm3), p < 0.001. The targets in Group 1 had statistically lower diameters for short and long axes, even after correction for gland size. The highest area under the receiver operating characteristic curve was demonstrated when a lesion cutoff value of 1.0 cm in short axis was applied, resulting in a sensitivity of 83.3 % and a specificity of 82.9 %.ConclusionsWhen a combined systematic and targeted transperineal prostate biopsy is performed, there is limited benefit in acquiring additional cores from larger-volume targets with a short axis diameter >1.0 cm.

Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis.

e15060 Background: Previously, we showed neoadjuvant chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) provides a reasonable chance of curative surgery in initially unresectable gastric cancer (GC) with invasion to adjacent organs or paraaortic lymph node (PAN) metastasis (Ann Surg Oncol 2010;17:1024-32). The aim of this study is to evaluate the efficacy and safety of more intensified neoadjuvant DXP+ bevacizumab (BEV) in these patients (pts). Methods: Eligibility criteria included ≥ 18 years, ECOG PS 0-2, and unresectable GC with invasion to adjacent organs or PAN metastasis of > 1 cm in short axis on CT with uptake on 18F-FDG-PET. Pts received 6 cycles of neoadjuvant chemotherapy (docetaxel 60 mg/m2 iv on D1, capecitabine 937.5 mg/m2 twice daily on D1-14, cisplatin 60 mg/m2iv on D1, and BEV 7.5mg/kg iv on D1 every 3 weeks), followed by D2 surgery. The primary endpoint was the R0 resection rate. Results: Between July 2010 and December 2014, 31 pts were enrolled. Clinical characteristics were...

Comparative Sonoanatomy of Classic “Short Axis” Probe Position with a Novel “Medial-oblique” Probe Position for Ultrasound-guided Internal Jugular Vein Cannulation: A Crossover Study

BackgroundUltrasound (US)-guided short-axis approach for internal jugular vein (IJV) cannulation does not fully protect patients from inadvertent carotid artery (CA) puncture. Carotid puncture is not rare (occurring in up to 4% of all IJV cannulations) despite the use of US. ObjectivesCompare the sonoanatomy of the “medial-oblique approach” probe position with the classic US-guided “short-axis” probe position, specifically: relation of internal CA and IJV; vertical and horizontal diameter of IJV; and degree of overlapping of IJV with CA. MethodsOne hundred consecutive patients between the ages of 18 and 50 years, both male and female, and American Society of Anesthesiologists Physical Status classification system (ASA PS) I–II undergoing elective surgery under general anesthesia were recruited in this prospective, randomized, crossover, parallel-group study. ResultsThe transverse diameter of the IJV was found to be significantly higher in the medial-oblique probe position (p = 0.000, mean difference 0.43 cm; 95% confidence interval [CI] 0.34–0.52). The percentage of overlap was also significantly lower in the medial-oblique probe position (48.7 ± 10.7% in short-axis vs. 36.3 ± 13.2% in medial-oblique probe position; p = 0.000; mean difference 12.4%, 95% CI 9.1–15.8). However, there was no statistically significant difference in the anteroposterior diameter of the IJV between the two probe positions (1.11 ± 0.26 cm in short axis vs 1.07 ± 0.25 cm in medial oblique; p = 0.631). ConclusionThe medial-oblique probe position for IJV cannulation provides sonoanatomic superiority over the classic short-axis probe position. Further randomized, controlled trials may confirm the medial-oblique view's clinical benefit in the future.

CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer.

We investigated whether the initial CT distribution of metastatic disease is predictive of overall survival in patients with stage IV colorectal cancer. A retrospective study of 65 patients (37 males, 28 females, mean age 56, range 28-88 years) with stage IV colorectal cancer was derived from an institutional database. Inclusion criteria required KRAS mutation testing and pretreatment CT examinations to be available (65 abdomen/pelvis, 63 chest). Disease burden was jointly characterized by two radiologists in consensus. Median follow-up was 39 months (range 8-115 months). Survival was assessed using Cox proportional hazards models. Univariate analysis showed that stratified site(s) of measurable disease and counts of measurable lesions ≥1 cm in the liver, peritoneum, and retroperitoneum were statistically significant risk factors for overall mortality [univariate HR 8.2 (CI 2.7-25.4) for isolated peritoneal disease, HR 1.11 per 5 lesions (CI 1.05-1.17) for liver lesions, HR 1.15 per lesion (CI 1.05-1.26) for peritoneal lesions, and HR 1.11 (CI 1.03-1.19) for retroperitoneal lymph nodes ≥1 cm in short axis]. The stratified site(s) of disease and counts of measurable liver lesions remained significant in the multivariate model (p < 0.0001 for isolated peritoneal disease and count of liver lesions). Thoracic metastases were not statistically significant predictors of overall mortality in this cohort. This study identified site(s) of measurable metastasis and counts of measurable liver lesions as independent predictors of overall survival. These findings may have value for future prognostic assessments once validated in a larger, independent, and potentially prospective cohort.